Yihan Wang

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu et al. · Cancer Cell · 2009 · 1.2K citations · Full text

Hematological Malignancy, Tumor Biology, Chronic Myeloid Leukemia +9

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Wei‐Sheng Huang, Shuangying Liu, Dong Zou et al. · Journal of Medicinal Chemistry · 2016 · 392 citations · Full text

Drug Target, Anaplastic Lymphoma Kinase, Tumor Biology +18

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Sen Zhang, Rana Anjum, Rachel M. Squillace et al. · Clinical Cancer Research · 2016 · 321 citations · Full text

Characterization of Susceptibility of Inbred Mouse Strains to Diabetic Nephropathy

Zhonghua Qi, Hiroki Fujita, Jianping Jin et al. · Diabetes · 2005 · 297 citations · Full text

Glomerular Disease, Renal Pathology, Immunology +19

Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

Tianjun Zhou, Lois Commodore, Wei‐Sheng Huang et al. · Chemical Biology & Drug Design · 2010 · 282 citations